Pertuzumab biosimilar（Hisun Pharm）

帕妥珠单抗生物类似药（浙江海正）

Report date: 2026/03/20 20:03:07

Base Information

Drug NamePertuzumab biosimilar（Hisun Pharm）
Drug Alias NameRecombinant humanized anti-EGFR monoclonal antibody (Hisun Pharm/Mabworks Biotech)重组抗人表皮生长因子受体人源化单抗（天广实生物）重组人源化EGFR单抗（天广实生物）重组人源化表皮生长因子受体单抗（海正药业/天广实生物）HS-627 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesZhejiang Hisun Pharmaceutical Co LtdBeijing Mabworks Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBioRay Pharmaceutical Co LtdZhejiang Hisun Pharmaceutical Co LtdBeijing Mabworks Biotech Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A